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Summary Ondansetron is a selective 5-HT3 antagonist with significant antiemetic properties in patients
receiving cytotoxic chemotherapy. Patients who had suffered severe vomiting on carboplatin alone (23 patients
with ovarian carcinoma) or in combination (two patients with testicular cancer) despite intensive antiemetic
regimens were treated with ondansetron, given as 8 mg immediately prior to carboplatin followed by 8 mg
orally, 8 hourly for 5 days. Twenty-five patients received 58 courses of ondansetron. In the first 24 h after the
first course ofchemotherapy with ondansetron, 17 patients (68%) experienced no vomiting, five patients (20%)
had almost complete control and the other three patients had partial control. During the subsequent 4 days
slightly lesser control was achieved. Nausea was similarly controlled in most patients. Twenty-two patients
stated a preference for ondansetron with future chemotherapy. Fourteen patients received additional
chemotherapy with ondansetron and in only three patients did the efficacy of therapy lessen. Toxicity was mild
and transient with headache and constipation predominant. No extrapyramidal reaction was seen. Sedation
was absent. Ondansetron is highly effective in refractory vomiting associated with carboplatin chemotherapy.
It may be particularly beneficial when an extrapyramidal reaction has occurred on previous antiemetics and
when sedation is unacceptable.
Although carboplatin is significantly less emetogenetic than
cisplatin, most patients experience some nausea and/or
vomiting. For a proportion of patients emesis is severe,
despite aggressive antiemetic regimens. Most such antiemetic
regimens are based on moderate or high dose metoclo-
pramide, often with dexamethasone and lorazepam in addi-
tion. These regimens may themselves cause distressing side
effects, including extrapyramidal reactions and sedation.
(Roila et al., 1989).
Ondansetron, a selective 5-HT3 receptor antagonist, has
shown considerable antiemetic activity in uncontrolled
studies (Cunningham et al., 1987; Kris et al., 1988; Hesketh
et al., 1989; Einhorn et al., 1990). In randomised studies it
has been proven superior to both placebo (Cubeddu et al.,
1990) and high dose metoclopramide (Marty et al., 1990) in
controlling cisplatin induced emesis. In non-cisplatin contain-
ing chemotherapy regimens it has been shown superior to
metoclopramide in four randomised studies (Schmoll, 1989;
Kaasa et al., 1990).
Vomiting after most chemotherapeutic agents tends to
start within a couple of hours of treatment. The onset of
vomiting after carboplatin, however, is often delayed for
6-1Oh (Calvert et al., 1982) and there is no previous study
of the effect of ondansetron on carboplatin induced vomiting.
This paper reports our initial experience with ondansetron
in patients treated with carboplatin, who had proven refrac-
tory to a previous aggressive antiemetic regimen.
Patients and methods
Patients
Adult patients receiving carboplatin chemotherapy were eli-
gible for treatment with ondansetron if they had vomited
three times or more in the first 24 h of the previous course of
chemotherapy. However, patients were excluded if they had a
severe concurrent illness other than neoplasia, had hepatic
dysfunction other than due to metastases or were receiving
any other antiemetic medication, including benzodiazepines.
Twenty-three women with ovarian cancer receiving carbo-
platin alone (300-400 mg m-2) and two men with testicular
germ cell tumours receiving carboplatin (300 mgm2) with
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etoposide (120 mgm-2 days 1-3) were entered on protocol.
The median age was 52 years (rane 24-68 years). All patients
had multiple episodes of vomiting during the first 24 h of
their previous course of chemotherapy (Table I), with 18
patients having > 10 episodes. Nine patients had experienced
an extrapyramidal reaction and three patients found this
intolerable. The previous exposure to antiemetic regimens is
shown in Table I. Twenty-one patients had three or more
antiemetic drugs in their previous protocol.
Treatment
Ondansetron was given as 4 mg intravenously and 4 mg
orally immediately prior to chemotherapy with 8 mg orally
6 h and 12 h later. All patients received 8 mg TDS for' a
further 4 days. No other antiemetic medication was permit-
ted. This restriction included benzodiazepines, except when
these had been taken regularly by the patient as night seda-
tion prior to the study. Patients, who vomited on more than
five occasions, were considered to have failed ondansetron
therapy and were eligible for rescue antiemetic medication.
Assessment ofvomiting
A vomit was defined as any single vomit or retch or any
series of vomiting or retching within a 5 min period without
pause. Control of vomiting was recorded as; complete con-
trol (no episode) almost complete control (1-2 episodes)
partial control (three to five episodes) or failure (>five
episodes). Nausea, as estimated by the patient, was recorded
Table I Details of previous antiemetic therapy and emetic episodes
(A) Vomitingduringpreviousantiemeticregimen
3-9 Episodes 7 pts
10-19 Episodes l0pts
20 + Episodes 8pts
(B) Antiemeticdrugsgivenduringpreviouschemotherapy cycle
High dosemetoclopramide 22pts (2 mg kg-' 2-hourly x 3 -5 doses)
Moderatedosemetoclopramide 3pts (0.5-1 mg kg-' 2-hourly x 4
doses)
Lorazepam 16pts(1-2 mgPOpre-chemotherapy)
Dexamethazone 13pts (8 mgi.v. 6-hourly x 2doses)
Haloperidol 8 pts (2.5 mgi.v. 4-hourlyPRN)
'Scopaderm' patch 15 pts(1 patchpre-chemotherapy)
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as none, mild (not interfering with normal life) moderate
(interfering with normal daily life) or severe (bedridden due
to nausea). All patients were treated as out-patients and were
contacted at 24h by a research nurse to assess number of
vomits and grade of nausea experienced. Patients used a
diary card to record any nausea, vomiting or side effects of
therapy for the first 5 days. Each patient was reviewed by the
research nurse at 1 week, when diary cards were checked and
a pill count of unused ondansetron was made to assess
compliance.
At the end of each course of the treatment the patient was
asked to state their preferred antiemetic regimen for future
courses of treatment.
Statistics
Student's paired t-test was used to compare the incidence of
vomiting and nausea in the first 24 h with that in the subse-
quent 4 days during the first cycle of ondansetron therapy.
Ethical considerations
The proposed study was reviewed and approved by the
Research Ethics Committee of Auckland Hospital. The study
was conducted according to the principles of the Declaration
of Helsinki. All patients gave written informed consent in the
presence of an independent witness, prior to entry.
Results
Twenty-five patients received 58 cycles of chemotherapy with
ondansetron (median two cycles, range 1-7).
Efficacy
(a) First course ofchemotherapy with ondansetron Complete
control ofvomiting was achieved in 17 patients (68%) during
the first 24 h and 14 patients (56%) for the full 5 days (Table
II). All 25 patients had some control of vomiting during the
first 24 h, but five patients failed during the subsequent 4
days (P <0.002). Twenty-three of the 25 patients vomited
less than on their previous course of chemotherapy, when
they had been treated with standard antiemetics. Nausea was
similarly well controlled in most patients (Table II), although
this control was less adequate during days 2 to 5 (P <0.02).
Twenty-two patients elected to receive ondansetron in
subsequent courses of chemotherapy. Of the three patients
who declined further ondansetron, all had severe nausea
between days 2-5. Of the five patients who failed ondanset-
ron (>five vomits) on days 2-5, 3 patients requested further
ondansetron with future chemotherapy, because they had
nonetheless felt better than on the standard antiemetics,
given during the previous course of chemotherapy.
Table II Patient experience of nausea and vomiting on first cycle of
ondansetron
(A) Vomiting
No. episodes Day I Day 2-S
0 17 pts (68%) 14 pts (56%)
1-2 5 pts (20%) 1 pt (4%)
3-5 3 pts (12%) 5 pts (20%)
>5 5 pts (20%)
Day 1 vs days 2-5 P<0.002
(B) Nausea
Degree Day Day 2-5
None 14 pts (56%) 12 pts (48%)
Mild 9 pts (36%) 5 pts (20%)
Moderate 1 pt (4%) 2 pts (8%)
Severe 1 pt (4%) 6 pts (24%)
Day 1 vs days 2-5 P<0.02
(b) Subsequent courses of chemotherapy with ondansetron
Fourteen patients received ondansetron with subsequent
chemotherapy. Six patients received two cycles of ondanset-
ron. Five maintained their previous complete control, but
one patient failed on day 2. Eight patients received multiple
cycles. Four patients maintained complete control through-
out four to five cycles. Two patients experienced between
three to nine episodes of vomiting through each of four and
seven cycles of therapy, but elected to continue ondansetron
as giving better control than previous antiemetics. Two
patients developed increasing vomiting over three and four
cycles of therapy, leading to discontinuation of ondansetron.
Complete control of vomiting was achieved in nine of 14
patients during the second course of ondansetron therapy, in
three of eight patients during the third course, in four of
seven patients during the 4th course and in two of three
patients during the 5th course.
Toxicity
Toxicity was mild and is shown in Table III. There was no
episode of extrapyramidal reaction. The most common side
effect was a mild headache, and this occurred, usually with
each cycle of therapy, in 15 patients. It was often described
as 'a heavy head' and easily relieved by paracetamol. Thir-
teen patients complained of constipation during at least one,
and usually every, course of treatment. It was often described
as severe by the patient, but never required admission and
was always relieved by simple laxatives.
Other adverse events reported were less frequent. Abnor-
mal liver enzyme concentrations were noted in five patients,
but were mild (< 1.5 x upper limit of normal) in four patients
and severe (>3 x upper limit of normal) in only one patient.
All abnormalities were transient, settling without symptoms
or sequelae. No elevation of serum bilirubin occurred.
Nasal stuffiness occurred in three patients with rapid onset
and subsequent resolution. There were no other features of
allergy. Interestingly it did not occur in every cycle.
The abdominal pain noted by four patients was described
as both cramp and indigestion. It settled without therapy.
No patient complained of sedation during therapy. Indeed
13 patients (56%) specifically commented that the lack of
sedation (compared to that on the previous regimen) was an
additional feature in their selection of ondansetron for future
cycles of treatment.
Discussion
Previous studies have reported the efficacy of ondansetron in
controlling chemotherapy - induced vomiting resulting from
both cisplatin and non-cisplatin containing chemotherapy
regimens. The current study is the first to report the efficacy
of ondansetron in a group of patients with carboplatin -
induced vomiting, refractory to standard antiemetics.
In this study ondansetron prevented vomiting in 68% of
patients in the first 24 h and almost eliminated it in a further
20%. Similarly nausea was absent in 56% and mild in 36%
of patients in the first 24 h. This major effect on control of
vomiting in 88% and nausea in 92% of patients, who were
refractory to previous aggressive antiemetic regimens, is im-
pressive.
Major control of vomiting (60%) and nausea (68%) was
Table III Toxicity of ondansetron
Headache 15 pts (60%)
Constipation 13 pts (54%)
Abnormal liver function 5 pts (20%)
Abdominal pain 4 pts (16%)
Metallic taste 3 pts (12%)
Nasal stuffiness 3 pts (12%)
Diarrhoea 1 pt. (4%)944 V.J. HARVEY et al.
somewhat less between days 2 and 5, as has been found in
previous studies (Cubeddu et al., 1990; Einhorn et al., 1990;
Marty et al., 1990). It has been suggested that the mechanism
of delayed nausea and vomiting may differ from that during
the first 24 h. Clearly the activity of ondansetron beyond the
first 24 h requires further investigation.
Most published work on ondansetron focuses on the first
cycle of therapy. However, since most courses of
chemotherapy comprise several cycles of treatment and there
is a tendency for antiemetic control to lessen with repeated
treatment, we have been particularly interested in the activity
of ondansetron in subsequent cycles. Fourteen patients
received more than one course of chemotherapy and in only
three patients did the efficacy of ondansetron lessen during
further cycles.
All previous data have emphasised the low toxicity profile
of ondansetron and the current study supports this. No
extrapyramidal reaction occurred in 58 cycles of therapy, 18
given to patients who had experienced such a reaction on
metoclopramide previously. All other side effects were mild,
and most had been reported previously. However, three
patients complained of nasal stuffiness, a side effect not
previously noted. Despite continued treatment in all three
patients no other allergic manifestation was seen, although
there have been rare reports of allergic reactions following
administration of ondansetron including two reports of
anaphylaxis. (Data on File. Glaxo Group Research Ltd,
UK).
This study has shown excellent control of nausea and
vomiting by ondansetron, in the majority of patients, treated
with carboplatin, who were refractory to other antiemetic
regimens. Although it did not assess the activity of ondanset-
ron in chemotherapy naive patients receiving carboplatin, it
would be most surprising if ondansetron was not at least as
effective in this situation as in refractory patients (Einhorn et
al., 1990). The place of ondansetron in chemotherapy naive
patients awaits complete definition and will depend on many
factors, including the expected severity of side effects of
treatment, the ease of antiemetic administration and cost.
The authors wish to thank the staff of the Department of Clinical
Oncology for their care of the patients reported in this study. They
are grateful to Glaxo NZ Ltd for supplies of ondansetron and thank
Mrs H. Donaghue for typing the manuscript.
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